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Francesca Mascia1, Christophe Cataisson1, Tang-Cheng Lee2, David Threadgill2, Valentina Mariani3,
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and Saveria Pastore3,6
Recent advances in the knowledge of the EGFR pathway have revealed its contribution to distinct immune/
inflammatory functions of the epidermis. The purpose of our study was to evaluate the role of EGFR in the
regulation of keratinocyte GM-CSF expression. In cultured human keratinocytes, proinflammatory cytokines
synergized with TGF-a to induce GM-CSF expression. Accordingly, high epidermal levels of EGFR activation are
associated with enhanced expression of GM-CSF in lesional skin of patients with psoriasis or allergic contact
dermatitis. In cultured keratinocytes, pharmacological inhibition of EGFR activity reduced GM-CSF promoter
transactivation, whereas genetic inhibition of AP-1 reduced expression of GM-CSF. Furthermore, EGFR
activation enhanced TNF-a-induced c-Jun phosphorylation and DNA binding, whereas c-Jun silencing reduced
GM-CSF expression. Using two different mouse models, we showed that the lack of a functional EGFR pathway
was associated with reduced cytokine-induced phosphorylation of ERK1/2, JNK1/2, c-Jun and reduced
keratinocyte-derived GM-CSF expression both in vitro and in vivo. Finally, the analysis of GM-CSF expression
in the skin of cancer patients treated with anti EGFR drugs showed an association between ERK activity, c-Jun
phosphorylation, and epidermal GM-CSF expression. These data demonstrate that the EGFR pathway is critical
for the upregulation of keratinocyte GM-CSF expression under conditions of cytokine stimulation.
Journal of Investigative Dermatology (2010) 130, 682–693; doi:10.1038/jid.2009.336; published online 5 November 2009
INTRODUCTION
The epidermal growth factor receptor (EGFR) and its ligands
participate in the response of the epithelium to injury in
several target sites. In the skin, EGFR ligands are actively
synthesized by keratinocytes during acute wound healing,
and their sustained overexpression is a characteristic feature
in chronic inflammatory disorders including psoriasis, atopic
dermatitis and allergic contact dermatitis (Mascia et al.,
2003). Apart from their well-established mitogenic role (Jost
et al., 2000; Wetzker and Bo¨hmer, 2003), these growth
factors are involved in a number of immune protective
mechanisms. Transforming growth factor (TGF)-a, the major
endogenous EGFR ligand in human skin, promotes the
expression of several anti-microbial peptides (Sørensen
et al., 2003) and of Toll Like Receptor (TLR) -5 and -9, and
synergizes with these receptors in the induction of leukocyte
chemoattractants, which include anti-microbial peptides
themselves and CXCL8/IL-8 (Miller et al., 2005). Through
these mechanisms, the EGFR-ligand system creates a link
between innate and adaptive immune responses. Moreover,
TGF-a regulates tumor necrosis factor (TNF)-a and interferon
(IFN)-g induced levels of a cluster of chemokines implicated
in the massive recruitment of T cells, monocytes and
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immature dendritic cells, including the CXCR3 ligand IP-10/
CXCL10, MCP-1/CCL2 and RANTES/CCL5 (Mascia et al.,
2003). While activation of the EGFR-ligand system opposes
microbial colonization and promotes efficient wound clo-
sure, it prevents excessive leukocyte recruitment into the
skin. Noteworthy, the absence of a fully functional EGFR
pathway is associated with a mixed inflammatory infiltration
in the skin of both EGFR null mice and patients undergoing
chemotherapy with EGFR antagonists (Roberts et al., 2004).
EGFR is overexpressed and mutated in a variety of
malignancies and a number of different approaches that
aim to inhibit EGFR activation are currently in use or being
developed. The most common adverse effect seen with EGFR
inhibition therapy is a pronounced skin inflammatory
response (papulo-pustular rash) that can affect different areas
of the body with variable severity (Robert et al., 2005).
Recent studies suggest that the skin rash may represent a
valuable tool that helps in monitoring the efficacy of some
EGFR targeted drugs (Pe´rez-Soler et al., 2005; Melosky et al.,
2009). However, it is not known if the cutaneous rash is an
independent effect of the presence of the drug target in the
epidermis or if the inflammatory response is of more
relevance to the therapeutic response within the tumor. Thus
more investigative efforts are needed to better understand the
role of EGFR in the modulation of inflammatory mediators
expression in epithelial cells.
Granulocyte/macrophage-colony stimulating factor (GM-
CSF) is recognized as a major immune regulator governing
survival of granulocyte and macrophage lineage populations
at all stages of maturation (Hamilton, 2008). GM-CSF is
secreted by keratinocytes shortly after injury, and it is
considered an early response factor in tissue regeneration
(Florin et al., 2006). Transgenic mice overexpressing kerati-
nocyte-derived GM-CSF exhibit an accelerated wound
healing process with higher numbers of proliferating kerati-
nocytes at wound edges, increased formation of granulation
tissue and enhanced neovascularization (Mann et al., 2001).
Besides its activity in promoting angiogenesis and wound
healing in normal tissues (Valdembri et al., 2002), GM-CSF
has an important role in promoting angiogenesis and
malignant growth in squamous cell carcinomas of head and
neck (Gutschalk et al., 2006).
Given the relevance of EGFR and GM-CSF in skin and
cancer immunobiology, we investigated the in vitro and
in vivo control of the EGFR pathway on GM-CSF expression
in human and mouse keratinocytes and skin.
RESULTS
GM-CSF is overexpressed in chronic inflammatory skin
disorders
We previously reported that GM-CSF is strongly up regulated
in chronic lesions of atopic dermatitis patients (Pastore et al.,
1997). Here we report that high levels of this cytokine could
also be detected in the skin of patients suffering from psoriasis
(Figure 1b) or affected by allergic contact dermatitis (Figure
1c), whereas extremely low epidermal GM-CSF expression
was observed in healthy controls (Figure 1a). The epidermis
of the inflammatory conditions showed cytoplasmic, nuclear
and perinuclear GM-CSF staining (see Figure 1 insets).
Moreover a strong GM-CSF positivity was also associated
with inflammatory cells and endothelial cells in the upper
part of the dermis in the lesional skin (Figure 1b and c) and in
dermal endothelium of healthy skin (Figure 1a).
TGF-a synergizes with TNF-a and IFN-c for the induction of
GM-CSF in cultured human keratinocytes
In T cell-mediated inflammatory skin disorders including
atopic dermatitis, psoriasis and allergic contact dermatitis,
the epidermal compartment displays strong up-regulation of
TGF-a (Mascia et al., 2003). Although no data are presently
available on the specific role of EGFR signaling during GM-
CSF expression in keratinocytes in vivo, the concomitant high
levels of both TGF-a and GM-CSF in lesional skin could be
suggestive of a potentiation of GM-CSF expression by TGF-a.
We found that exogenous TGF-a alone was a poor
stimulus for GM-CSF mRNA expression in cultured human
keratinocytes. In these cells, TGF-a strongly synergized with
the pro-inflammatory cytokine TNF-a (Figure 2a) and induced
an earlier and stronger response to IFN-g stimulation (Figure
2b). By contrast, keratinocyte pretreatment with the selective
EGFR inhibitor PD168393 (PD16) prevented GM-CSF induc-
tion both by TNF-a (Figure 2a) and IFN-g (Figure 2b),
indicating that EGFR signaling is actively involved in
keratinocyte response to T cell-derived cytokines. These
effects were dependent on the concentration of TGF-a and
PD16, as confirmed at the protein level by ELISA in 24 hours
culture supernatants (Figure 2c and d).
We verified if the synergistic response observed between
TGF-a and TNF-a was restricted to this specific EGFR ligand
or other members of the EGF family could evoke a similar
response. To this aim we stimulated cultured keratinocytes
with equimolar concentration (10 nM) of EGF, HB-EGF,
Amphiregulin (AR) and TGF-a in presence or absence of
Figure 1. GM-CSF is highly expressed by epidermal keratinocytes in chronically inflamed skin. Expression of GM-CSF in the epidermis of a healthy donor (a), in
lesional skin of plaque psoriasis (b) and chronic allergic contact dermatitis (c). Representative immunohistochemistry results from seven healthy donors,
five patients with psoriasis, and three patients with allergic contact dermatitis. Normalization bar¼ 100mm for panel a ( 200) and 50mm for panels b and c ( 100).
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TNF-a. ELISA tests showed that TNF-a induced GM-CSF
expression was enhanced with a similar potency by TGF-a,
EGF and HB-EGF while AR was less effective in synergizing
with TNF- a (Supplementary Figure 1a).
EGFR activation is characterized by a homo/heterodimer-
ization with EGFR itself or other members of the HER family
of receptors. The preferred coreceptor of EGFR is represented
by HER2. We investigated the role of HER2 in the regulation
of TNF-a induced GM-CSF expression. In contrast to the
reduction of GM-CSF expression observed in keratinocytes
pretreated with PD16 (Figure 2a and Figure 2d), pretreatment
with a specific HER-2 inhibitor, Herceptin, did not affect the
expression of GM-CSF at the mRNA and protein level
(Supplementary Figure 1c and Figure 1d). At the selected
doses Herceptin was able to induce HER2 degradation
while not affecting EGFR levels (Supplementary Figure 1b)
(Hudis, 2007).
TGF-a upregulates TNF-a induced GM-CSF transcription via
increased c-Jun phosphorylation and transactivation
We have previously reported that effective transactivation of
the minimal GM-CSF promoter, namely p91CAT, requires
cooperation between activator protein (AP)-1 and nuclear
factor kB (NFkB) binding sites in keratinocytes (Pastore et al.,
2000). Hence, this minimal promoter represents a valid tool
to investigate the interplay between EGFR-directed and TNF-a-
driven signaling pathways on GM-CSF gene transcription.
We have also reported that EGFR activation promotes
gene expression in keratinocytes through enhanced AP-1
whereas it does not affect NFkB, whose transcriptional
activity is promoted by TNF-a (Pastore et al., 2005).
Basal activity of the minimal GM-CSF promoter was only
slightly perturbed by TGF-a, whereas this growth factor
synergized with TNF-a with a three-fold increase over TNF-a-
driven reporter gene expression (Figure 3a). Of note, the
selective pharmacological inhibition of EGFR by PD16
impaired GM-CSF promoter activity following induction by
TNF-a. A similar inhibitory effect was exerted by the selective
blockade of ERK1/2 by PD98059 (PD98), or JNK1/2 by
SP600125 (SP600).
Endogenous GM-CSF protein release examined by ELISA
in the supernatant of transfected keratinocytes closely
paralleled GM-CSF promoter activity, confirming that the
control of GM-CSF expression by EGFR signaling and
downstream kinases was at the transcriptional level (Figure
3b). The dominant negative form of AP-1, A-FOS, is able to
sequester AP-1 monomers and prevents their binding to DNA
thereby suppressing AP-1 transcriptional activity (Olive et al.,
1997). Human keratinocytes were stimulated for 24 hours
with TNF-a in the presence (TGF-a) or absence (PD16) of
EGFR activation and transduced with an adenovirus expres-
sing A-FOS. A dose-dependent inhibition of GM-CSF release
into culture supernatants was observed in all the conditions
tested when AP-1 activity was reduced (Figure 3c). The same
culture conditions were used to study proximal events
upstream of GM-CSF release. To this aim lysates isolated
from human keratinocytes stimulated for 15 and 30 minutes
were analyzed by western blot and with an ELISA-based DNA
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Figure 2. TGF-a enhances, whereas EGFR signaling inhibition suppresses, the expression of GM-CSF by cytokine-stimulated human keratinocytes. Cytokine
gene expression was measured by RNase protection assay in total RNA (10 mg) extracted from human keratinocytes stimulated with TNF-a (50 ng/ml) (a) or IFN-g
(50 U/ml) (b) and/or TGF-a (50 ng/ml), directly or following 30 minutes incubation with PD168393 (1mM). The autoradiographies are representative of four
independent experiments. ELISA detection of GM-CSF levels after 24 hours stimulation of human keratinocytes with escalating doses of TGF-a (c) or PD168393
(PD16) (d). Results are expressed as the mean of three independent experiments±SD.
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binding assay. In this assay higher optical density (OD) values
represent higher levels of a specific transcription factor bound
to its cognate DNA sequence. Western blot analysis of human
keratinocytes treated for 15 minutes showed that TNF-a
induced an increase in phosphorylation levels of c-Jun in
serine 63 (Figure 3d). EGFR activation by TGF-a or inhibition
by PD16 was able to respectively potentiate or decrease TNF-a
induced serine 63 phosphorylation of c-Jun. This residue has
an important role in the transactivating function of AP-1
transcription factor (Smeal et al., 1991). In the same
conditions, we observed that while c-Fos DNA binding was
only slightly affected, c-Jun binding to AP-1 consensus was
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Figure 3. TGF-a upregulates GM-CSF transcription via increased c-Jun phosphorylation and transactivation. (a) CAT activity was determined in human
keratinocytes transfected with the minimal GM-CSF promoter p91CAT following 6 hours stimulation with 50 ng/ml TNF-a and/or 50 ng/ml TGF-a directly, or
following 30 minutes pre-incubation with 2 mM PD168393 (PD16), or 20 mM PD98059 (PD98) or SP600125 (SP600). (b) ELISA of GM-CSF levels in the
supernatant of keratinocytes after 24 hours stimulation with same conditions as panel a. (c) GM-CSF ELISA detection of culture supernatants 48 hours after
infection of human keratinocytes with increasing doses of A-FOS or null adenovirus. Cells were treated in the last 24 hours with TNF-a (50 ng/ml) and/or TGF-a
(50 ng/ml), directly or following 30 minutes incubation with PD168393 (1 mM). (d) Twenty mg of total cell lysates were run in an immunoblot to detect phospho
c-Jun (ser 63) levels or used to evaluate the relative DNA binding activity versus an AP-1 binding site in (e) where c-Jun/c-Fos DNA binding was tested by
TransAM assay. For these experiments, keratinocytes were treated for 15 minutes (panel d) or 30 minutes (panel e) with TNF-a (50 ng/ml) and/or TGF-a
(50 ng/ml), directly or following 30 minutes incubation with PD168393 (1 mM). (f) GM-CSF mRNA levels were quantified by real-time RT-PCR with and without
c-Jun silencing in human keratinocytes stimulated for 4 hours with TNF-a (50 ng/ml) and/or TGF-a (50ng/ml), directly or following 30minutes incubation with
PD168393 (1mM). (g) Total levels of c-Jun and EGFR were detected via immunoblot as control for silencing experiment. Values in (a–c) and (f ) are expressed as
the mean of experimental duplicates±SD. *Po0.01. Panels d and g show one representative experiment. All experiments were repeated at least three times.
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maximal when TNF-a and TGF-a were co-administered
(Figure 3e). In addition, human keratinocytes were trans-
fected with a siRNA targeting c-Jun or a control siRNA
sequence, and cell lysates and RNAs were assayed for total
c-Jun levels and GM-CSF mRNA expression (Figure 3f and g).
In presence of lower levels of c-Jun protein, TNF-a and TGF-a
failed to fully induce GM-CSF mRNA. c-Jun is an important
upstream modulator of EGFR transcription and when its
expression is completely abrogated in mice, EGFR levels are
strongly reduced (Zenz et al., 2003). In our silencing
condition, in human keratinocytes, in which c-Jun levels
are reduced of about 70% of the original amount, EGFR
transcription and expression still occurs at a normal rate.
Overall, these data suggested that TNF-a induced GM-CSF
transcription depended on EGFR and c-Jun activity.
Genetic ablation of EGFR prevents full induction of GM-CSF,
and maximal phosphorylation of ERK 1/2, JNK 1/2 and c-Jun
in vitro and in vivo
To determine whether genetic ablation of EGFR impacted
GM-CSF regulation, neonatal mouse keratinocytes were
isolated from EGFR null mice (Threadgill et al., 1995) and
stimulated with TNF-a in the presence (TGF-a) or absence
(PD16) of EGFR activation (Figure 4a). After 1 hour stimula-
tion of wild type cells, TGF-a or TNF-a elicited a small
increase of GM-CSF mRNA expression. As seen for human
keratinocytes, the combination of TGF-a and TNF-a gave a
synergistic response, while the pharmacologic inhibition of
EGFR reduced TNF-a induced GM-CSF levels. A similar
response was detected at the protein level after 24 hours
stimulation (Figure 4b). Interestingly, keratinocytes isolated
from EGFR null pups showed a decreased capacity to fully
upregulate GM-CSF expression after TNF-a stimulation
(Figure 4a and Figure 4b). In parallel, if compared to
keratinocytes from wild type littermates, ERK1/2, JNK1/2
and c-Jun phosphorylation levels were reduced in keratino-
cytes of EGFR null mice (Figure 4c lanes 9 versus 3 and lanes
11 versus 5). Figure 4d shows the densitometric analysis of
the phosphorylated form of c-Jun normalized by the total
c-Jun band. In wild-type keratinocytes the phosphorylation of
c-Jun increased over the basal level at 10 minutes and
returned to baseline level after 1 hour of stimulation by
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Figure 4. Genetic ablation of EGFR impairs TNF-a-induced GM-CSF expression and ERK1/2, JNK1/2, and c-Jun phosphorylation in murine keratinocytes.
(a) real-time RT-PCR for murine GM-CSF on wild-type and EGFR null keratinocytes. Cells were stimulated for 1 hour with TNF-a (50 ng/ml) and/or TGF-a
(50 ng/ml), directly or following 30 minutes incubation with PD168393 (1mM). (b) ELISA of cell supernatant after 24 hours stimulation as panel a.
(c) Keratinocytes from wild-type (lanes 1–6) and EGFR null mice (lanes 7–12) were stimulated for 10 minutes and 1 hour with TNF-a (50 ng/ml) or TGF-a
(50 ng/ml), directly or following 30 minutes incubation with PD168393 (1 mM). Twenty mg of cell lysates were subjected to immunoblotting. (d) Densitometric
analysis of phospho c-Jun bands normalized over total c-Jun bands of immunoblot from panel c. Values in (a) and (b) are expressed as the mean of experimental
duplicates±SD. *Po0.01. Experiments were repeated at least three times with one representative experiment shown in the figure.
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TNF-a. At all timepoints, EGFR ablated keratinocytes showed
lower levels of the phosphorylated form of c-Jun. Keratino-
cytes from EGFR null mice displayed low levels of an
alternatively spliced variant detected with the EGFR antibody
at 140-kDa, as previously described (Dlugosz et al., 1997).
This alternatively spliced form could account for the faint
induction of ERK1/2 and JNK 1/2 after TGF-a stimulation and
the small reduction of ERK1/2 and JNK 1/2 phosphorylation
in the presence of the EGFR inhibitor PD16.
To confirm our in vitro observations in vivo, we examined
the level of activation of ERK1/2, JNK1/2, c-Jun and the levels
of GM-CSF in skin tissue lysates and tissue sections. To this
aim, we exploited a second mouse model with a skin targeted
deletion of EGFR. These mice were created by crossing
Keratin 5 promoter-driven Cre recombinase transgenics
(Ramirez et al., 2004) with mice containing loxP sites
flanking exon 3 of the EGFR gene (Lee and Threadgill,
2009). Double transgenic deleted mice, Tg(K5Cre)/Egfr (f/f) did
not display a specific defect at birth but, at the end of the first
week of life, showed a strong skin phenotype that resembled
that of the EGFR null mice (Threadgill et al., 1995). In
contrast to EGFR null mice, skin targeted mutants survive for
months and maintain a skin inflammatory phenotype that is
currently under investigation.
TPA painting of mouse skin induces the upregulation of
GM-CSF expression in total skin extracts (Koury et al.,
1983). We treated the back skin of double (Tg(K5Cre)/Egfr(f/þ ):
wild type for EGFR and Tg(K5Cre)/Egfr(f/f): EGFR deleted)
transgenic mice with 10 mg TPA for 2 hours and 7 hours and
harvested the whole skin for tissue lysates and histology
respectively. Immunohistochemical staining for total leu-
kocytes (blue staining¼CD45 positive cells) showed a
highly abundant infiltrate in EGFR ablated skin while sparse
cells were detected in untreated skin of littermate controls.
TPA treatment increased the number of CD45 infiltrating
cells in EGFR expressing skin but not in the highly infiltrated
skin of EGFR ablated mice. TPA administration caused an
increase in GM-CSF levels in EGFR competent double
transgenics both in the dermal and in the epidermal
compartment while it did not affect the basal level in the
epidermis of EGFR ablated double transgenics. In spite of
the highly abundant leukocyte presence, EGFR ablated
mice did not express higher levels of GM-CSF in the
epidermis than wild type controls. Thus epidermal GM-CSF
expression was not associated with the degree of leukocyte
infiltration in EGFR ablated skin. Cultured keratinocytes
from EGFR null skin were less responsive than wild type
cells to TPA stimulation in terms of GM-CSF mRNA
expression (Figure 5b). These data showed that keratino-
cytes lacking EGFR failed to fully upregulate GM-CSF
expression both in vitro and in vivo during an inflammatory
event. The profile of phosphorylation of ERK1/2, JNK1/2
and c-Jun in skin samples mirrored the levels that we
observed in isolated keratinocytes lysates. The skin of EGFR
ablated mice showed overall lower levels of phospho-
ERK1/2, phospho-JNK1/2 and lower total and phospho-c-
Jun levels when compared to correspondent lysates from
EGFR competent skin (Figure 5c).
Epidermal GM-CSF levels in cetuximab-associated skin rash are
highly variable and correlate with ERK1/2 and c-Jun
phosphorylation levels but not the inflammatory infiltrate
A papulo-pustular rash is a common adverse effect of several
anti EGFR drugs. Noteworthy, the degree of severity and
intensity of the eruption is variable within patients, and it is
reversible when the treatment is withdrawn. By immunohis-
tochemistry we detected GM-CSF, phospho-ERK1/2, phos-
pho-c-Jun and CD45 expression in human skin samples
obtained from inflamed skin of patients undergoing che-
motherapy with cetuximab and displaying grade II lesions.
Serial sections of the skin of 3 representative patients (#1, #2,
#3) are shown in Figure 6 compared with normal control
skin. Even though all the patients showed a high levels of
CD45 staining they displayed variable expression levels of
epidermal GM-CSF. Thus, we could not correlate epidermal
GM-CSF expression with the abundance of the local
inflammatory infiltrate. The variable degree of GM-CSF
expression in different patients was associated with the
phosphorylation levels of ERK1/2 and c-Jun.
DISCUSSION
In the current study we broaden the concept of EGFR as a skin
immunomodulator by adding GM-CSF to the pool of
inflammatory mediators that are regulated by EGFR activity.
The EGFR ligand TGF-a, potentiates keratinocyte response to
the pro-inflammatory cytokines TNF-a and IFN-g with an
enhanced expression of GM-CSF. This synergy is likely active
in the lesional skin of chronic inflammatory diseases, and
helps to explain the intense GM-CSF staining that we found in
the skin lesions from patients with atopic dermatitis (Pastore
et al., 1997), but also in allergic contact dermatitis and
psoriasis. Strong TGF-a expression characterizes the whole
epidermis of lesional skin from patients with these disorders
(Mascia et al., 2003), whereas TNF-a and IFN-g are locally
released by a variety of infiltrating leukocyte populations,
which include dendritic cells, monocytes, mast cells and
T cells. In turn, these cytokines not only induce the release of
the mature form of TGF-a from its membrane precursor
(Mascia et al., 2003), but they also effectively stimulate its de
novo expression by keratinocytes (Valyi-Nagy et al., 1992;
Matsuura et al., 1999). The enhancement of cytokine-
induced GM-CSF expression by TGF-a closely resembled
what we previously described for CXCL8 in cultured
keratinocytes (Mascia et al., 2003), and suggests that both
GM-CSF and CXCL8 are part of a TGF-a-driven amplification
circuit during keratinocyte response to skin inflammation.
GM-CSF is considered a pro-inflammatory cytokine, since
it contributes to the establishment of a favorable milieu for
the recruitment, functional differentiation and survival of a
variety of leukocyte cell populations, including monocytes
and dendritic cells (Hamilton, 2008). High expression of GM-
CSF in the lesional skin of atopic patients has been implicated
in the facilitated recruitment and maturation of dendritic cell
progenitors in this disease (Hamid et al., 1994; Pastore et al.,
1997). In addition, we reported that keratinocytes cultured
from nonlesional skin of atopic dermatitis patients release
abnormal levels of GM-CSF in response to proinflammatory
www.jidonline.org 687
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stimuli, and reasonably contribute to GM-CSF accumulation
in atopic lesions in vivo (Pastore et al., 1997, 2000).
Analogously, the direct correlation between GM-CSF and
TNF-a levels in the suction blister fluids from psoriatic lesions
suggested the contribution of GM-CSF in the pathogenesis of
this disease (Bonifati et al., 1994). However, a direct
evidence for a pro-inflammatory effect associated with high
levels of GM-CSF in the epidermis has not been provided.
Transgenic mice overexpressing GM-CSF in the basal layer of
the epidermis display accelerated re-epithelialization of full-
thickness skin wounds, characterized by higher numbers of
proliferating keratinocytes at the wound edges and increased
formation of granulation tissue (Mann et al., 2001). A
selective accumulation of Langerhans cells and mast cells
could be observed in the epidermis, without evident signs of
active inflammation (Breuhahn et al., 2000). When injected
intradermally into the human skin, GM-CSF induces epider-
mal thickening, with accumulation of dermal CD1þ , Birbeck
granule-positive Langerhans cells, but no evidence of T cell,
monocyte or granulocyte recruitment or changes in cell-
mediated immune responses (Kaplan et al., 1992; Braunstein
et al., 1994). Finally, intradermal injection of recombinant
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Figure 5. Skin-targeted deletion of EGFR impairs TPA-induced epithelial GM-CSF expression in vivo. (a) Immunohistochemical detection of CD45 in skin
sections from double transgenic wild-type (Tg(K5Cre)/Egfr(f/þ )) and double transgenic EGFR deleted (Tg(K5Cre)/Egfr (f/f)) mice, untreated and treated with 10 mg of
TPA for 7 hours. Immunohistochemical detection of GM-CSF in skin sections from double transgenic wild-type and double transgenic EGFR deleted mice,
untreated and treated with 10mg of TPA for 7 hours. Normalization bar¼ 50mm. (b) real-time RT-PCR for murine GM-CSF on wild-type and EGFR null
keratinocytes. Cells were stimulated for 1 hour with 5 and 50 ng/ml of TPA directly or following 30 minutes incubation with PD168393 1 mM. (c) Double
transgenic wild-type (Tg(K5Cre)/Egfr(f/þ )) and double transgenic EGFR deleted (Tg(K5Cre)/Egfr (f/f)) mice were treated for 2 hours with vehicle alone or 10 mg of TPA
and 50mg of tissue lysates were immunoblotted. Experiments were repeated at least three times with one representative experiment showed in the figure. Values
in (b) are expressed as the mean of experimental duplicates±SD. *Po0.01.
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human GM-CSF around chronic venous ulcers can be
successfully employed to accelerate wound closure (Stagno
et al., 1999; Cianfarani et al., 2006). We speculate that during
an inflammatory response in the skin, as already suggested in
inflammatory conditions of the lungs and colon (Abdul
Rhaman et al., 2004; Korzenik et al., 2005), GM-CSF may not
necessarily contribute to the aggravation of the flogistic
response but its enhanced expression could participate to the
clearance of the inflammatory condition through a promotion
of the wound healing response. In this study we demonstrated
that functional EGFR signaling was involved in TNF-a-
induced GM-CSF expression in human and murine keratino-
cytes. The genetic deletion of the EGFR pathway is associated
with impaired wound healing response (Repertinger et al.,
2004). Our data showed a strong association between EGFR
activity and GM-CSF expression and it is possible that the
delayed wound healing response observed in EGFR null skin
could depend on the insufficient expression of this cytokine
in the epidermis.
We demonstrated that the abrogation of EGFR signaling by
specific EGFR tyrosine kinase inhibition caused a marked
decrease of GM-CSF transcription associated with suppres-
sion of ERK1/2 activity. In contrast, the blockade of Her-2 did
not affect GM-CSF expression. Previous papers have already
established that functional ERK1/2 activity plays a relevant
role in GM-CSF gene expression in human epithelial cells,
including keratinocytes (Reibman et al., 2000; Kanda and
Watanabe, 2004; Matsubara et al., 2004).
With our study we identified EGFR and c-Jun as important
regulators of TNF-a induced GM-CSF promoter activity. In
particular we showed that c-Jun phosphorylation and c-Jun
DNA binding activity is maximally activated by combined
treatment with TGF-a and TNF-a. In parallel, inhibitors of
EGFR or genetic abrogation of this pathway prevented the full
induction of c-Jun phosphorylation both in vitro and in vivo.
Due to the lack of higher number of samples we could not do
an extensive study to correlate GM-CSF levels, ERK1/2 and
c-Jun phosphorylation to the extent of the skin rash, the
amount or the quality of skin infiltrating cells or the tumor
response to the drug. In the small subset of patients on anti-
EGFR therapy that we analyzed, the amount of skin
inflammatory infiltrate was not directly related to the levels
Healthy
skin
#1
#2
#3
GM-CSF p-c-Junp-ERK1/2 CD45
Figure 6. Epidermal GM-CSF expression levels in the inflamed skin of cetuximab treated patients are associated with phosphorylation levels of ERK1/2 and
c-Jun and not with CD45 staining. Skin sections of three representative patients and one control are shown. Patients were affected by cetuximab-induced skin
rash (grade II). GM-CSF, phospho ERK1/2, phospho c-Jun, and CD45 immunohistochemistry were performed on serial sections from the same patient.
Normalization bar¼ 50mm for  200 magnification of GM-CSF, phospho ERK1/2, and phospho c-Jun staining. Normalization bar ¼ 25 mm for  100
magnification of CD45 staining.
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of GM-CSF expressed in the epidermis. Nevertheless in all
patients studied, GM-CSF levels in the epidermis were
consistently associated with ERK1/2 and c-Jun phosphoryla-
tion levels, confirming the relevance for the human system of
data obtained in vitro and in the mouse models. We
speculate that GM-CSF might not have a pathogenetic role
in the lesions formed after treatment with cetuximab. Further
studies are needed to confirm if epidermal GM-CSF, can be
used as a surrogate marker for drug efficacy evaluation.
GM-CSF stimulates proliferation and migration of trans-
formed epithelial cells suggests a possible role of this factor in
tumor progression and invasion (Mueller and Fusenig, 1999;
Gutschalk et al., 2006). Since GM-CSF expression is among
the transcription-controlled events downstream of the EGFR/
ERK1/2 pathway in epithelial cells, it is possible that
suppression of GM-CSF may play a relevant role in the
anti-cancer mechanisms triggered by the EGFR inhibitors
presently employed for the therapy of EGFR-dependent
epithelial cancers. These hypotheses are currently under
investigation. Previous work associated the expression levels
of an epithelial cell derived chemokine with tumor progres-
sion (Pivarcsi et al., 2007). These authors highlighted the role
of EGFR in CCL27 expression both in vitro in Ras transformed
cells, in skin with epithelial tumors and in lesions from
Erlotinib treated patients. Altogether, these and our indepen-
dent observations underline the need of further study on the
role of EGFR and EGFR blockade into the creation of a
selective environment that shapes the immune system
response within the skin and possibly within the tumor.
MATERIALS AND METHODS
Subjects
Four-mm punch biopsies were taken from lesional skin of adult
patients with chronic plaque psoriasis (n¼ 5; two females and three
males; age 30–48), chronic allergic contact dermatitis (n¼ 3; two
females and one male; age 30–40), cetuximab-associated skin rash
grade II, according to Melosky et al., 2009 (n¼ 9, three females and
six males, age 50–66) and normal skin of healthy subjects (n¼ 7; two
females and two males; age 24–59). Epidermal sheets for keratino-
cyte cultures were obtained from healthy individuals undergoing
plastic surgery (mammoplasty or abdominoplasty) (n¼ 4, two
females and two males; age 25–40). None of the patients had
received oral corticosteroids within 1 month of skin explant, and
topical corticosteroids were not allowed for a period of at least
2 weeks prior to enrolment. All subjects gave written informed
consent prior to enrolment. These studies were conducted according
to the Declaration of Helsinki Guidelines and were approved by the
institutional review boards of the Istituto Dermopatico dell’Imma-
colata (healthy donors and patients affected by psoriasis and allergic
contact dermatitis) and the Universita‘ di Chieti and Pescara (patients
treated with anti EGFR therapy).
Cell cultures
Primary cultures of normal human keratinocytes were obtained as
previously described (Pastore et al., 1997), and routinely grown in
serum-free Epilife Medium from Invitrogen (Carlsbad, CA), prepared
from an essential nutrient solution supplemented with HKGS growth
supplement kit that contains: 0.2 ng/ml EGF, 0.18 mg/ml hydrocorti-
sone, 5mg/ml bovine transferrin, 0.2% bovine pituitary extract, 5mg/ml
bovine insulin and antibiotic solution of Gentamicin/Amphotericin.
In the 24 hours preceding the experiments, 80% confluent cell
cultures were switched to EGF and hydrocortisone-depleted
medium. All assays were performed on human keratinocytes
obtained from at least three distinct healthy donors. Newborn
mouse keratinocytes were cultured as described in Lichti et al.,
2008.
Mice and treatment
Mouse studies were performed under a protocol approved by the
National Cancer Institute and the NIH Animal Care and Use
Committee. Homozygous or heterozygous EGFR null mice and wild-
type siblings on a CD-1 background were developed using
homologous recombination in 129/Sv-derived D3 embryonic stem
cells. Mice were genotyped as described elsewhere. (Threadgill
et al., 1995). The construction and characterization of K5Cre mice
were previously described (Ramirez et al., 2004). K5Cre mice
express Cre Recombinase under the promoter of bovine Keratin 5
that targets the transgene to the basal layer of the epidermis and the
outer root sheath of the hair follicle. EGFR floxed mice containing
loxP sites flanking exon 3 of the EGFR gene (Lee and Threadgill,
2009) were crossed with K5Cre mice to obtain double transgenic
mice with EGFR deletion in the epidermis (Tg(K5Cre)/Egfr (f/f)). The skin
of the above mentioned mice was compared with double transgenic
littermates that were heterozygous for the EGFR floxed allele
(Tg(K5Cre)/Egfr(f/þ )). In vivo experiments were performed by painting
the back skin of shaved mice with 10 mg of TPA from Axxora (San
Diego CA).
Cytokines and chemicals
Recombinant human TGF-a, Amphiregulin, EGF, HB-EGF, TNF-a
and IFN-g were purchased from R&D Systems (Minneapolis, MN).
The small molecule, cell-permeant protein kinase inhibitors
PD168393 and AG1478 (EGFR inhibitor), PD98059 (ERK1/2
inhibitor), and SP600125 (JNK1/2 inhibitor) were from Calbiochem
(La Jolla, CA). Herceptin was purchased from Genentech Inc.,
(San Francisco, CA). Human IgG was purchased from Sigma
(St Louis, MI).
RNA isolation, RNAse protection assay and real-time RT-PCR
Total RNA was extracted from keratinocytes using the TRIzol
Reagent, according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). The templates of human GM-CSF and the house-
keeping molecule L32, and the kit for RNase protection assay were
purchased from BD Biosciences (San Diego, CA). Total RNA (10mg)
was hybridized overnight with a-32ATP-labeled cDNA templates,
and reactions were performed per the manufacturer’s instructions.
For cDNA synthesis, 1 mg of total RNA was reverse transcribed
using SuperScript II Reverse Transcriptase (Invitrogen). PCR were
performed in a volume of 20 ml using iQ SYBR Green Supermix from
BIORAD (Hercules, CA) and 1:100 dilution of cDNA. Primers used
for this analysis were as follows: human GAPDH from Gene Link
(Hawthorne NY), human GM-CSF 5‘: GAAGTCATCTCAGAAATG
TTTGACCTC, 3‘: GGTCTGTAGGCAGGTCGGC, mouse GM-CSF
5‘: GGAGGATGTGGCTGCAGAAT, 3‘: GGCTGTAGACCACAATG
CCC and mouse GAPDH 5‘: CATCGCCTTCCGTGTTCCTA, 3‘:
GCGGCACGTCAGAATCCA. Real Time analysis was performed
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using a Bio-Rad iCycler iQ and Gene Expression Macro (version
1.1). Results are presented as relative quantity±SD from at least
three independent experiments.
Cell lysates and western blot
Total cell lysates were prepared from human and murine keratino-
cytes cultures with cold RIPA buffer freshly additioned with
antiprotease cocktail from Roche (Mannheim, Germany), 1 mM
sodium orthovanadate, 1 mM sodium fluoride. Cell lysates were
vortexed and incubated on ice for 10 minutes and then centrifuged at
14,000 rpm for 15 minutes. Supernatants were quantified with
Bradford method and used for western blot or TransAM assays
(Active Motif, Carlsbad, CA). Total lysates from skin samples were
treated as follows: skin was excised and snap frozen in liquid
nitrogen and cold processed at 2,000 rpm for 2 minutes in a Mikro-
Dismembrator S from Sartorius (Goettingen, Germany). Powderized
skin was then lysed with cold RIPA buffer as previously described.
Twenty mg of protein lysates were run on poliacrylamide gels under
denaturing conditions and then transferred on PVDF membranes for
protein detection. All primary and HRP secondary antibodies were
from Cell Signaling (Boston, MA).
Enzyme-Linked Immunosorbent Assay (ELISA) and TransAM
assay
Quantitation of GM-CSF was performed on cell-free supernatants
using ELISA kits from R&D Systems (Abingdon, United Kingdom).
Data are expressed as nanograms or picograms per 106 cells±SD
from three independent experiments. TransAM is an ELISA based
assay kit to detect and quantify transcription factor activation.
Twenty mg of total cell lysates from human keratinocytes were used
for each condition on the AP-1 family kit (44296) from Active Motif
(Carlsbad, CA). Results were read on a spectrophotometer and data
are expressed as O.D. optical density±SD. Experiments were
performed in duplicates with three independent repeats.
Plasmid construct and keratinocyte transfection
The chloranphenicol-acetyltransferase (CAT) reporter construct
carrying the sequence of the minimal GM-CSF promoter, from 91
nucleotides upstream to 23 nucleotides downstream of the GM-CSF
cap site (p91 GM-CSF CAT), has been previously described
(Kaushansky, 1989). For transfection experiments, we followed the
procedure previously described (Pastore et al., 2000). CAT activity in
cell lysates was measured using CAT ELISA kit from Roche
(Mannheim, Germany). Results are plotted p91CAT activity±SD
from duplicates values of three independent experiments.
Adenovirus infection and siRNA transfection
A dominant negative AP-1 vector, A-FOS, or empty vector control,
Null, were introduced into human keratinocytes using an adenoviral
construct driven by a cytomegalovirus promoter (Olive et al., 1997).
Sixty percent confluent keratinocytes were infected with increasing
amounts of A-FOS adenovirus in 0.3 ml/6 well plates in order to
enhance viral uptake. Ten to forty MOI (multiplicity of infection from
10 viral particles/cell to 40 viral particles/cell) were used in this
experiment. After 90 minutes. of infection, additional 2 ml of
starvation medium were added to the cells. After 24 hours cells
were stimulated for additional 24 hours before collecting super-
natants. Human keratinocytes were treated with c-Jun siRNA
(Cat. No. SI00300580) or non targeting siRNA (Cat No.
D-001210–02–20) from Qiagen (Valencia, CA) and Dharmacon
(Lafayette, CO) respectively. Cells were transfected with 100 nM
siRNA and RNAiFect transfection reagent from Qiagen according to
manufacturer‘s instruction. Effective silencing was verified by
western blot.
Immunohistochemistry
Paraffin embedded sections of biopsies fixed with 4% paraformal-
dehyde, were incubated with citrate buffer pH 6 and microwaved for
3 minutes at high power. Slides were allowed to cool down for
20 minutes. at room temperature, treated with 3% hydrogen
peroxide, and then incubated for 1 hour with 10% goat serum. After
overnight incubation at 4 1C with the appropriate primary dilution of
each antibody, slides were treated for 1 hour at room temperature
with the corresponding secondary antibody. For the detection of
GM-CSF, phospho ERK1/2, c-Jun and CD45 in human tissues, we
employed: sc-13101 (1:10) from Santa Cruz Biotech (Santa Cruz,
CA), 9101 and 2361 (1:50) from Cell Signaling (Boston MA) clone
2B11þ PD7/26 from DAKO (Glostrup, Denmark); for the detection
of GM-CSF in mouse tissue we used AF-415-NA (1:15) from R&D
Systems (Abingdon, United Kingdom)and for mouse CD45 we used
(1:100) CD45-AF 114 from R&D Systems (Minneapolis, MN).
Secondary biotinylated antibodies and staining kits were from
Vector Laboratories (Burlingame Laboratories, CA). Immunoreactiv-
ity was revealed using avidin-biotin-peroxidase system and AEC
(Figure 1) or DAB (Figure 5 and Figure 6) as chromogen or alkaline
phosphatase system and AP-blue as substrate, all from Vector
Laboratories (Burlingame Laboratories, CA). CD45 staining (AP-blue,
blue staining) for human tissue was performed as a second staining
after phospho c-Jun staining (DAB, brown staining). Sections were
counterstained with Mayer’s hematoxylin or Vector Red.
Statistical analysis
The Wilcoxon signed-rank test (GraphPad Prism software, La Jolla,
CA) was applied to compare differences between groups of data.
Significance was assumed at a P-value of 0.05 or less.
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